Posted by Michael Wonder on 02 Mar 2018
Biogen and AbbVie announce the voluntary worldwide withdrawal of marketing authorisations for Zinbryta (daclizumab) for relapsing multiple sclerosis
2 March 2018 - Patient safety is the top priority for Biogen and AbbVie.
Biogen and AbbVie today announced the voluntary worldwide withdrawal of Zinbryta for relapsing multiple sclerosis. The companies believe that characterising the complex and evolving benefit/risk profile of Zinbryta will not be possible going forward given the limited number of patients being treated.
Biogen will continue to work collaboratively with regulatory authorities in the withdrawal of product and with healthcare providers worldwide in their support of Zinbryta patients.
